---
schema_version: "secwatch.filing_event.v1"
accession: "0001599298-25-000066"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2025-04-25T23:59:59+00:00"
generated_at: "2026-05-23T05:51:56.839879+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Summit: Ivonescimab gets second NMPA approval in China; OS hazard ratio 0.777

## Summary
- NMPA approved ivonescimab for front-line PD-L1+ advanced NSCLC based on HARMONi-2 Phase III trial.
- Interim OS analysis showed hazard ratio 0.777 (22% reduction in risk of death) at 39% data maturity.
- Primary endpoint PFS previously showed HR 0.51 (p<0.0001) favoring ivonescimab over pembrolizumab.
- Summit is enrolling HARMONi-7, a multiregional Phase III trial of ivonescimab vs pembrolizumab in same population.

## SEC filing metadata
- accession: 0001599298-25-000066
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2025-04-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000159929825000066/0001599298-25-000066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000159929825000066/smmt-20250425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001599298-25-000066
- JSON: https://secwatch.observer/filing/0001599298-25-000066.json
- Plain text: https://secwatch.observer/filing/0001599298-25-000066.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.